First in Human Study of M4344 in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2021-09-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of multiple ascending
doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily
dose schedule in participants with advanced solid tumors. This investigation is a three part
study examining M4344 alone and in combination with carboplatin to determine the safety and
maximum tolerated dose.
Phase:
Phase 1
Details
Lead Sponsor:
EMD Serono Research & Development Institute, Inc. Vertex Pharmaceuticals Incorporated